The success of GLP-1 receptor agonists/analogues has transformed metabolic disease treatment while demonstrating the potential of engineered peptides to deliver long-acting, highly targeted therapies.
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results